Insmed Inc.
NASDAQ · INSM·Bridgewater, NJ·Large-cap·Approved
Rare disease company with Arikayce (amikacin liposome inhalation) for MAC lung disease and brensocatib (DPP1 inhibitor) approved for bronchiectasis. Insmed's pipeline targets serious pulmonary and rare inflammatory conditions with novel mechanisms.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Insmed Investor Presentation March 2026 | Corporate overview | March 27, 2026 | 75 |